EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 3.0

Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study

Na Zhao, Lijun Zhu, Xing Hu, Juan Tong iD, Hongfeng Ge, Li Ye, Xijun Zhu, Can Gai, Yuhu Feng, Lei Zhang, Li Wang, Guangyu Sun und 3 weitere

Blood and Lymphatic Cancer: Targets and Therapy · 2026-04 · Volume 16 · 1-12

DOI: 10.2147/blctt.s592550 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Blood and Lymphatic Cancer: Targets and Therapy, 2026-04. Verfasst von Na Zhao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of Chin…. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

hypomethylating agentsmyelodysplastic syndromesvenetoclax

Autor:innen und Institutionen

  • Department of Hematology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230000, People's Republic of China.
  • State Key Laboratory of Immune Response and Immunotherapy, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230000, People's Republic of China.
  • Department of Hematology, Bozhou People's Hospital, Bozhou, Anhui, 233500, People's Republic of China.
  • Department of Hematology, Lu'an People's Hospital, Lu'an, Anhui, 237000, People's Republic of China.
  • Department of Hematology, Xuancheng People's Hospital, Xuancheng, Anhui, 242000, People's Republic of China.
  • Department of Hematology, Huaibei People's Hospital, Huaibei, Anhui, 235000, People's Republic of China.

ORCID-Profile: Juan Tong, Xiaoyu Zhu, Changcheng Zheng

Zitieren

APA

Zhao, N., Zhu, L., Hu, X., Tong, J., Ge, H., Ye, L., Zhu, X., Gai, C., Feng, Y., Zhang, L., Wang, L., Sun, G., Xue, L., Zhu, X., & Zheng, C. (2026). Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study. Blood and Lymphatic Cancer: Targets and Therapy, Volume 16, 1-12. https://doi.org/10.2147/blctt.s592550

Vancouver

Zhao N, Zhu L, Hu X, Tong J, Ge H, Ye L, et al. Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study. Blood and Lymphatic Cancer: Targets and Therapy. 2026;Volume 16:1-12. doi:10.2147/blctt.s592550

BibTeX
@article{Zhao2026,
  author = {Zhao, Na and Zhu, Lijun and Hu, Xing and Tong, Juan and Ge, Hongfeng and Ye, Li and Zhu, Xijun and Gai, Can and Feng, Yuhu and Zhang, Lei and Wang, Li and Sun, Guangyu and Xue, Lei and Zhu, Xiaoyu and Zheng, Changcheng},
  title = {Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study},
  journal = {Blood and Lymphatic Cancer: Targets and Therapy},
  year = {2026},
  volume = {Volume 16},
  pages = {1--12},
  doi = {10.2147/blctt.s592550}
}
Kostenlos starten →